Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 2 November 2026.
Announcements
293
Total raised
£10.5B
disclosed amounts
The funding round was backed by Wayra UK, Octopus Ventures, and Macquarie to support the rollout of Raylo Pay.
"There is a clear shift in consumer behaviour and their preference for subscription based payment models. There’s an appetite for more affordable options to purchase great technology and devices. The Raylo team has proven success in delivering on this consumer trend, and we look forward to helping them scale up their platform through our strategic resources and networks."
The pre-IPO financing comes from a cornerstone investor to support affordable mRNA vaccine development and modular manufacturing.
"Normax is on a social mission to redress global healthcare inequity caused by the profiteering pharmaceutical industry. Following the recent €300 million capital commitment in Normax, we plan to deliver research and development of mRNA vaccines for COVID, TB, HIV, and Malaria and deploy modular mRNA Vaccine Factories, ultimately in up to 100 locations. In the event of another public health emergency we are also committed to delivering future mRNA vaccines in 100 days, to help ensure that COVID-19 is the last pandemic we will all suffer through,"
Jenson Funding Partners backed the London-based online dermatology service to support platform development and service expansion.
"Without the ability to quickly and easily see a dermatologist, patients often go for months or even years without receiving proper treatment for acne, which can have a huge impact on emotional and mental health as well as the risk of causing permanent scarring. Typically, their treatment journey begins with online research, with resources varying in reliability, before trialling over-the-counter skincare products, which are not sufficient in a lot of cases,"
Maven Capital Partners backed the Manchester-based identity and access management platform to fund acquisitions and technical growth.
"Our partnership with Maven is a major milestone for ProofID. This investment gives us the platform to add new services and vendor partnerships to our portfolio to better serve our customers. We are excited about the prospect of working with the team at Maven to grow and develop our business over the coming years."
The syndicate included Mark Bamforth, Tern Plc, SIS Ventures, and Scottish Enterprise.
"2022 promises to be a big year for Talking Medicines with this new investment. Having scaled up our operations and formally launched our PatientMetrx® technology platform, we’ve now got our sights set on expanding in the US pharma market, providing brand teams and agencies with a new way of understanding what patients are really saying and feeling about their medicines. The pharmaceutical industry will go through seismic change this year and our actionable patient insights will be transformational for the industry. Our new office in New Jersey provides the ideal base for us to build relationships with customers, acquire new leads and drive revenue growth."
